AAS
MRNA icon

Avantax Advisory Services’s Moderna MRNA Stock Holding History

Avantax Advisory Services’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$261K Buy
9,455
+1,368
+17% +$36K ﹤0.01% 2022
2025
Q1 		$229K Sell
8,087
-3,535
-30% -$125K ﹤0.01% 2014
2024
Q4 		$483K Buy
+11,622
New +$555K ﹤0.01% 1468
2024
Q3 		– Sell
-5,894
Closed -$700K – 2173
2024
Q2 		$700K Buy
5,894
+859
+17% +$109K 0.01% 1166
2024
Q1 		$537K Buy
5,035
+1,750
+53% +$176K ﹤0.01% 1001
2023
Q4 		$327K Sell
3,285
-2,592
-44% -$218K ﹤0.01% 1196
2023
Q3 		$607K Buy
5,877
+11
+0.2% +$1.23K 0.01% 865
2023
Q2 		$713K Sell
5,866
-163
-3% -$21.7K 0.01% 802
2023
Q1 		$926K Sell
6,029
-140
-2% -$23.1K 0.01% 685
2022
Q4 		$1.11M Sell
6,169
-1,635
-21% -$267K 0.01% 607
2022
Q3 		$923K Buy
7,804
+164
+2% +$24.9K 0.01% 580
2022
Q2 		$1.09M Buy
7,640
+2,578
+51% +$368K 0.02% 521
2022
Q1 		$874K Sell
5,062
-204
-4% -$34.3K 0.01% 585
2021
Q4 		$1.34M Sell
5,266
-838
-14% -$245K 0.02% 447
2021
Q3 		$2.35M Buy
6,104
+205
+3% +$75.6K 0.04% 309
2021
Q2 		$1.39M Buy
5,899
+34
+0.6% +$6.08K 0.03% 406
2021
Q1 		$770K Sell
5,865
-309
-5% -$44.8K 0.02% 492
2020
Q4 		$642K Sell
6,174
-1,028
-14% -$104K 0.02% 481
2020
Q3 		$511K Buy
+7,202
New +$502K 0.01% 777

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Avantax Advisory Services's MRNA Position: Q2 2025 in Review

Avantax Advisory Services increased its Moderna (MRNA) stake by 17% in Q2 2025, buying an estimated $36K and bringing the position to 9,455 shares worth $261K. The position accounts for ﹤0.01% of the portfolio, ranked #2022.

Avantax Advisory Services first reported a position in MRNA in Q3 2020 and has held it in 19 quarters since. The position peaked at $2.35M in Q3 2021. 674 funds tracked by Wall St. Rank hold MRNA as of Q2 2025.

  • Avantax Advisory Services held 9,455 shares of Moderna worth $261K as of Q2 2025.
  • Avantax Advisory Services bought 1,368 Moderna shares in Q2 2025, an estimated $36K.
  • Moderna made up ﹤0.01% of Avantax Advisory Services's portfolio in Q2 2025, its #2022 holding.
  • Avantax Advisory Services first reported a position in Moderna in Q3 2020 and has held it in 19 quarters since.
  • Avantax Advisory Services's Moderna position peaked at $2.35M in Q3 2021.
  • 674 funds tracked by Wall St. Rank held Moderna as of Q2 2025.

Based on Avantax Advisory Services's 13F filing for Q2 2025, filed 8 Aug 2025.